The urgent vaccine imperative: Sustaining visceral leishmaniasis elimination

Abstract

In October 2023, Bangladesh became the first country validated by the World Health Organization for eliminating visceral leishmaniasis (VL) as a public health problem. This achievement rests on robust case detection, effective treatment, and sustained vector-control interventions; however, these measures are resource intensive, vulnerable to political and funding disruptions, and may be undermined by population displacement and emergent drug resistance. Post-kala-azar dermal leishmaniasis reservoirs now outnumber primary VL cases in Bangladesh, while East Africa accounts for 73% of global VL cases with zoonotic transmission and exophilic sand fly behavior complicating control. The human vaccine pipeline remains concerningly thin: no licensed human vaccine exists, no phase III VL-specific efficacy trials are underway, and correlates of immune protection remain undefined. On the balance of current evidence, vaccination offers a potentially durable strategy to interrupt transmission independently of passive case detection and to reduce reliance on programmatic activities that are operationally fragile. Several factors in 2026 create a strategic inflection point for accelerated vaccine development and deployment, including Bangladesh’s validation, East Africa’s 2023-2030 elimination framework, and advances in next generation platforms (for example, mRNA and reverse-vaccinology approaches). We recommend planning multi-country phase III trials by 2027 with VL-relevant endpoints, establishing dedicated funding mechanisms, and integrating a future vaccine into regional elimination frameworks to maximize publichealth impact. Rapid, coordinated progress toward an effective vaccine is essential to safeguard and sustain the gains achieved to date. This review synthesizes current evidence on epidemiology, vaccine development, and programmatic challenges and proposes pragmatic priorities to accelerate VL vaccine evaluation and policy translation.

Keywords

Visceral leishmaniasis / Elimination sustainability / Vaccine development / Bangladesh / East Africa

References

[1] World Health Organization. Bangladesh achieves historic milestone by eliminating kala-azar as a public health problem. 2023. [Online]. Available from: https://www.who.int/news/item/31-10-2023-bangladesh-achieves-historic-milestone-by-eliminating-kala-azar-as-a-public-health-problem. [Accessed on 3 June 2026].

[2] Gupta PCS. History of Kala-Azar in India. Ind Med Gaz 1947; 82(5): 281-286.

[3] Nagi N. Bangladesh eliminates visceral leishmaniasis. Lancet Microbe 2024; doi: https://doi.org/10.1016/S2666-5247(24)00028-4.

[4] World Health Organization. Leishmaniasis: 20 years of progress towards elimination in the WHO African Region. 2025. [Online]. Available from: https://www.who.int/publications/i/item/9789290315766. [Accessed on 3 June 2026].

[5] Geto AK, Berihun G, Berhanu L, Desye B, Daba C. Prevalence of human visceral leishmaniasis and its risk factors in Eastern Africa: A systematic review and meta-analysis. Front Public Health 2024; 12: 1488741. doi: https://doi.org/10.3389/fpubh.2024.1488741.

[6] Chatterjee M, Roy S, Croft SL. Challenges in sustaining the elimination of visceral leishmaniasis in India. Int Health 2025; 17(6): 863-865.

[7] Mo AX, Pesce J, Fenton Hall B. Visceral leishmaniasis control and elimination: Is there a role for vaccines in achieving regional and global goals? Am J Trop Med Hyg 2016; 95(3): 514-521.

[8] World Health Organization. Strategic framework for the elimination of visceral leishmaniasis as a public health problem in eastern Africa 2023-2030. 2024. [Online]. Available from: https://www.who.int/publications/i/item/9789240094208. [Accessed on 3 June 2026].

[9] Chowdhury R, Hazarika A, Sultana S, Hossain MS, Saha S, Nabi SG, et al. Elimination of visceral leishmaniasis as a public health problem in Bangladesh: Lessons learned and questions remaining. PLoS Negl Trop Dis 2026; 20(2): e0013949. doi: https://doi.org/10.1371/journal.pntd.0013949.

[10] Paul S, Basher A, Aftab KA, Murshed KM, Kader MA, Chowdhury FR. Relapse Kala-azar: A potential threat to sustaining public health elimination in Bangladesh and ways to overcome it. J Med 2025; 26: 131-141.

[11] Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6(11): 849-854. doi: 10.1046/j.1365-3156.2001.00778.x.

[12] World Health Organization. African Nations unite to eliminate visceral leishmaniasis and boost cross-border collaboration for NTDs. 2025. [Online]. Available from: https://www.who.int/news/item/22-05-2025-african-nations-unite-to-eliminate-visceral-leishmaniasis-and-boost-cross-border-collaboration. [Accessed on 3 June 2026].

[13] Alvar J, den Boer M, Dagne D. Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: Reflections on an enhanced control strategy and a call for action. Lancet Global Health 2021; 9: e1763-e1769. doi: https://doi.org/10.1016/S2214-109X(21)00392-2.

[14] Rao GR, Kishore MRR, Singh R, Haritha K. Diagnosis of post Kala Azar dermal leishmaniasis in nonendemic areas: A clinical challenge. Clin Dermatol Rev 2022; 6(1): 56.

[15] Zijlstra EE, Alves F, Rijal S, Arana B, Alvar J. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme. PLoS Negl Trop Dis 2017; 11(11): e0005877. doi: https://doi.org/10.1371/journal.pntd.0005877.

[16] Ghosh D, Sagar S, Uddin MR, Rashid MU, Maruf S, Nath R, et al. Post kala-azar dermal leishmaniasis burden at the village level in selected high visceral leishmaniasis endemic upazilas in Bangladesh. Int J Infect Dis 2024; 147: 107213. doi: https://doi.org/10.1016/j.ijid.2024.107213.

[17] Fan Y, Gu Y, Tong X, He Y, Li Q, Chen K, et al. Efficacy and safety of different drugs for the treatment of leishmaniasis: A systematic review and network meta-analysis. Front Cell Infect Microbiol 2025; 15: 1717863. doi: https://doi.org/10.3389/fcimb.2025.1717863.

[18] Zhang H, Yan R, Liu Y, Yu M, He Z, Xiao J, et al. Progress in antileishmanial drugs: Mechanisms, challenges, and prospects. PLoS Negl Trop Dis 2025; 19(1): e0012735. doi: https://doi.org/10.1371/journal.pntd.0012735.

[19] Chowdhury R, Chowdhury V, Faria S, Islam S, Maheswary NP, Akhter S, et al. Indoor residual spraying for kala-azar vector control in Bangladesh: A continuing challenge. PLoS Negl Trop Dis 2018; 12(10): e0006846. doi: https://doi.org/10.1371/journal.pntd.0006846.

[20] Poché DM, Garlapati RB, Mukherjee S, Torres-Poché Z, Hasker E, Rahman T, et al. Bionomics of Phlebotomus argentipes in villages in Bihar, India with insights into efficacy of IRS-based control measures. PLoS Negl Trop Dis 2018; 12(1): e0006168. doi: https://doi.org/10.1371/journal.pntd.0006168.

[21] Garlapati R, Iniguez E, Serafim TD, Mishra PK, Rooj B, Sinha B, et al. Towards a sustainable vector-control strategy in the post Kala-Azar elimination era. Front Cell Infect Microbiol 2021; 11: 641632. doi: https://doi.org/10.3389/fcimb.2021.641632.

[22] Picado A, Das ML, Kumar V, Kesari S, Dinesh DS, Roy L, et al. Effect of village-wide use of long-lasting insecticidal nets on visceral leishmaniasis vectors in India and Nepal: A cluster randomized trial. PLoS Negl Trop Dis 2010; 4(1): e587. doi: https://doi.org/10.1371/journal.pntd.0000587.

[23] Ochol D, Haile K, Onduma N, Yohanes T, Kamara K. Elimination of visceral leishmaniasis in Ethiopia: Cross-sector collaboration and cost sharing to promote sustainability. Int J Infect Dis 2025; 152: 107800. doi: https://doi.org/10.1016/j.ijid.2025.107800.

[24] Alvar J, Beca-Martínez MT, Argaw D, Jain S, Aagaard-Hansen J. Social determinants of visceral leishmaniasis elimination in Eastern Africa. BMJ Global Health 2023; 8: e012638. doi: https://doi.org/10.1136/bmjgh-2023-012638.

[25] Olliaro P, Mondal D, Diro E, Mpanju-Shumbusho W. Visceral leishmaniasis elimination in South Asia: Lessons learnt can inform disease elimination in East Africa. BMJ Global Health 2026; 11: e023521. doi: https://doi.org/10.1136/bmjgh-2026-023521.

[26] Stanford University. Human-Centered Artificial Intelligence. 2026. [Online]. Available from: https://hai.stanford.edu/ai-index/2026-ai-index-report/medicine. [Accessed on 3 June 2026].

[27] Engwerda CR, Matlashewski G. Development of Leishmania vaccines in the era of visceral leishmaniasis elimination. Trans R Soc Trop Med Hyg 2015; 109(7): 423-424.

[28] Le Rutte EA, Coffeng LE, Malvolti S, Kaye PM, de Vlas SJ. The potential impact of human visceral leishmaniasis vaccines on population incidence. PLoS Negl Trop Dis 2020; 14(7): e0008468. doi: https://doi.org/10.1371/journal.pntd.0008468.

[29] Dinc R. Leishmania vaccines: The current situation with its promising aspect for the future. Korean J Parasitol 2022; 60(6): 379-391.

[30] World Health Organization. Leishmaniasis vaccines product development and existing challenges. 2024. [Online]. Available from: https://cdn.who.int/media/docs/default-source/immunization/pdvac/pdvac-2025/day-2/5.-leishmaniasis-vaccine-development.pdf?sfvrsn=ecd9df06_1. [Accessed on 3 June 2026].

[31] Yona C, Dey AK, Moshiro E, Lupala A, Macha M. Leishmaniasis vaccine development: A review of current candidates and cross-species protection potential. Parasitologia 2026; 6(2): 16.

[32] Ayala A, Llanes A, Lleonart R, Restrepo CM. Advances in Leishmania vaccines: Current development and future prospects. Pathogens 2024; 13(9): 812.

[33] Passero LFD, Cavallone IN, Araújo Flores GV, de Lima Melchert SS, Laurenti MD. An overview of the factors related to Leishmania vaccine development. Vaccines (Basel) 2026; 14(1): 54.

[34] European partnership on one health antimicrobial resistance (OHAMR). Joint transnational call 2026. 2026. [Online]. Available from: https://ohamr.eu/calls/call-2026-new-treatments-to-tackle-amr/. [Accessed on 3 June 2026].

[35] Drugs for neglected diseases initiative (DNDi). Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis. 2025. [Online]. Available from: https://dndi.org/press-releases/2025/six-african-nations-commit-eliminate-visceral-leishmaniasis/. [Accessed on 3 June 2026].

[36] Kaye PM, Matlashewski G, Mohan S, Rutte EL, Mondal D, Khamesipour A, et al. Vaccine value profile for leishmaniasis. Vaccine 2023; 41(2): S153-S175.

[37] Mohan S, Revill P, Malvolti S, Malhame M, Sculpher M, Kaye PM. Estimating the global demand curve for a leishmaniasis vaccine: A generalisable approach based on global burden of disease estimates. PLoS Negl Trop Dis 2022; 16(6): e0010471. doi: https://doi.org/10.1371/journal.pntd.0010471.